Arthneeti

Cipla Q2 FY27 Share Price & Earnings Call Analysis

₹1,358.00-0.56% today
Market cap
₹1.10L Cr
P/E
30.65
ROE
11.60%
PEG
3.00
Price to sales
3.88
Debt to equity
0.02
52W high / low
₹1,581 / ₹1,192
Sales growth (5Y)
8.01%
EBITDA margin
18.70%
Net profit margin
13.45%
Promoter holding
29.22%
Sales (last year)
₹28,324 Cr

Incorporated in 1935, Cipla Ltd is in the business of manufacturing, developing, and marketing a wide range of branded and generic formulations and APIs[1]

Guidance scorecard · Q2 FY27 call

What Cipla Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology

#45of 83 in
Pharmaceuticals & Biotechnology
Revenue10–20%MarginsUp 0–2%CapexPlannedFundraisingWhat management saidOrder bookWhat management said

RevenueQ1 FY27 call

10–20%
  • Cipla targets meaningful growth leading to a $1 billion exit in North America, driven by large new product launches expected to ramp up through the year.
  • New product launches in the U.S. (including 3 respiratory assets and a key peptide opportunity) are expected to contribute significantly to revenue, with supply scaling towards the end of the financial year.
  • India business is focused on sustaining growth momentum with a double-digit growth trajectory, especially in chronic therapies like respiratory, diabetes, cardiology, urology, and dermatology. Chronic portfolio in India is targeted to increase from 60%…

2 more points from Cipla Ltd's call on revenue

Create a free account to keep reading this call

Full Q1 FY27 analysis

MarginsQ1 FY27 call

Up 0–2%

See what Cipla Ltd said on margins — free account, 30 seconds.

Full Q1 FY27 analysis

CapexQ1 FY27 call

Planned
  • Cipla has increased capex focused on organic growth.
  • Significant investments are directed toward R&D, especially biosimilars.
  • The company is actively pursuing differentiated portfolios through acquisitions or in-licensing, which may require upfront payments.

2 more points from Cipla Ltd's call on capex

Create a free account to keep reading this call

Full Q1 FY27 analysis

FundraisingQ1 FY27 call

See what Cipla Ltd said on fundraising — free account, 30 seconds.

Full Q1 FY27 analysis

Order bookQ1 FY27 call

  • Cipla is expecting growth driven by new product launches, especially in the U.S. with three respiratory products and one large peptide product awaiting approval and launch.
  • The U.S. business aims for a $1 billion exit revenue run rate in FY27, relying significantly on these new product launches.
  • India business expects stable manpower with focus on productivity rather than large additions, indicating steady order processing.

2 more points from Cipla Ltd's call on the order book

Create a free account to keep reading this call

Full Q1 FY27 analysis
Full Pharmaceuticals & Biotechnology ranking

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Cipla Ltd rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹556 Cr22.1
240%+Up 0–2%₹215 Cr22.2
340%+Flat₹16,144 Cr—
440%+Flat₹6,072 Cr48.0
540%+Flat₹40 Cr—
620–40%Up 2%+₹50,220 Cr43.8

Sign up free to see every company in the sector ranking and track Cipla Ltd.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Cipla Ltd

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Cipla Ltd

Shareholding breakup across reporting periods.

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +33.46%33.46%30.91%30.93%29.19%29.20%29.19%29.22%29.22%29.22%29.22%29.20%
FIIs +25.73%25.82%27.82%28.80%26.65%26.28%25.24%24.54%23.93%22.55%20.20%20.24%
DIIs +24.05%24.15%24.66%23.95%27.49%27.89%28.98%29.98%30.45%31.71%34.35%34.61%
Government +0.21%0.21%0.21%0.21%0.23%0.26%0.27%0.27%0.27%0.27%0.28%0.33%
Public +16.53%16.36%16.40%16.11%16.43%16.36%16.30%15.99%16.12%16.26%15.93%15.60%
No. of Shareholders4,25,7314,36,1544,63,5694,70,2345,25,1145,43,4205,49,6555,34,5875,40,5215,84,2175,78,6795,62,798

Financials of Cipla Ltd

Quarterly Results

Quarter-by-quarter operating performance

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales +6,6786,6046,1636,6947,0517,0736,7306,9577,5897,0746,5417,1197,404
Expenses +4,9444,8564,8474,9785,1655,0845,1925,1795,6955,8195,5865,9276,016
Operating Profit1,7341,7481,3161,7161,8861,9891,5381,7781,8951,2559551,1921,388
OPM %26%26%21%26%27%28%23%26%25%18%15%17%19%
Other Income +176-10249160191222289259269-70148211151
Interest26301818151514141314131717
Depreciation290233288247272280309253297278383304345
Profit before tax1,5941,4741,2591,6111,7891,9161,5041,7701,8548937071,0821,177
Tax %28%28%26%27%27%17%19%27%27%24%22%27%27%
Net Profit +1,1551,0689321,1751,3051,5751,2141,2921,353674543786852
EPS in Rs14.0113.0811.6314.5816.1319.4515.1316.0616.738.376.879.7710.86

Financials of Cipla Ltd

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +11,34513,79014,39415,15616,36217,13219,16021,76322,75325,77427,54828,16328,139
Expenses +9,18311,31011,89812,32913,26513,92614,90717,21117,72619,48320,42022,28023,349
Operating Profit2,1632,4802,4962,8263,0973,2064,2524,5535,0276,2917,1285,8834,790
OPM %19%18%17%19%19%19%22%21%22%24%26%21%17%
Other Income +16420820828047734426699293552862606441
Interest16820715911416819716110611090625461
Depreciation5057541,3231,3231,3261,1751,0681,0521,1721,0511,1071,2111,310
Profit before tax1,6541,7271,2221,6692,0792,1783,2903,4934,0385,7026,8215,2243,859
Tax %24%19%15%15%27%29%27%27%30%27%22%26%
Net Profit +1,2291,3831,0351,4171,4921,5002,3892,5472,8334,1545,2693,8622,854
EPS in Rs14.7116.9312.5117.5218.9619.1829.8231.1934.7151.0565.2848.0235.87
Dividend Payout %14%12%16%17%16%21%17%16%24%25%25%27%

Financials of Cipla Ltd

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital161161161161161161161161161161162162162
Reserves10,64111,35612,38314,06814,85115,60218,16520,68023,24626,54531,03234,27035,234
Borrowings +1,7035,2024,1134,0984,3162,8162,0141,056803559438614699
Other Liabilities +3,1664,3314,2134,3464,4334,8434,5144,9605,0895,2675,7027,2977,339
Total Liabilities15,67021,04920,86922,67323,76223,42324,85526,85729,30032,53337,33442,34343,434
Fixed Assets +6,8309,3689,4929,9509,6089,6839,5169,6839,1609,60710,00612,43413,661
CWIP5812,0611,6839816768259697661,0931,1531,5662,0421,711
Investments6407599731,2592,5541,4712,7102,5513,6625,4497,9338,2236,686
Other Assets +7,6208,8628,72110,48310,92311,44411,66113,85715,38416,32317,82819,64321,376
Total Assets15,67021,04920,86922,67323,76223,42324,85526,85729,30032,53337,33442,34343,434

Financials of Cipla Ltd

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +1,1731,7412,3821,4631,6913,0683,7553,3263,2384,1345,0053,940
Cash from Investing Activity +-950-4,533-1,304-834-1,688114-2,374-1,858-2,376-2,982-3,682-2,234
Cash from Financing Activity +1653,104-1,326-385-349-2,949-1,240-1,600-958-1,200-1,293-1,234
Net Cash Flow388312-248243-345234141-132-97-4930473
Free Cash Flow5486881,2847231,1872,0832,9642,6452,1022,8193,490928
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit72%91%113%77%74%122%113%98%90%91%94%94%

Financials of Cipla Ltd

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days646265759383665765687373
Inventory Days329273239271250267232230228217231252
Days Payable126106108142123139103108112102116123
Cash Conversion Cycle267230196204220211195180181182188202
Working Capital Days89-10991181321139495113120128106
ROCE %15%13%7%9%11%12%17%17%18%23%23%15%

Guidance history

How Cipla Ltd's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q1 FY27 call →10–20%Up 0–2%Planned——
Q4 FY26 call →10–20%FlatPlanned——
Q3 FY26 call →10–20%FlatPlanned——
Q2 FY26 call →10–20%Down 0–2%Planned——

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

52out of 100

Momentum score · price trend

52 out of 100 — Steady

Over the past year its share price has moved roughly in the middle of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months−12.9%45%
Last 6 months+3.6%60%
Last 3 months−7.4%50%
How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Cipla Ltd: 0.4 × 45 + 0.4 × 60 + 0.2 × 50 = 52.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 28 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

What Cipla Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Lincoln Pharmaceuticals Ltd (Q2 FY27)

    2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it

  • Alivus Life Sciences Ltd (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest

  • Strides Pharma Science Ltd (Q2 FY27)

    Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation

  • Laurus Labs Ltd (Q2 FY27)

    2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd